The market's expectations for PROG Holdings were not met, given the contrast between EPS growth and share price decline. The company's future performance is uncertain, urging investors to consider other factors, including risks and financials, before deciding.
The company's P/E ratio reflects limited expected future growth, leading investors to pay a reduced amount for the stock. Unless PROG Holdings improves its earnings outlook, the company's share price is likely to remain at current levels.
Gainers: •$Clovis Oncology (CLVS.US)$+40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial) •$Dare Bioscience (DARE.US)$+13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO) •$KULR Technology (KULR.US)$+9.5% (secured a battery sa...
14
1
Report
No comment yet
- No more -
Sign in to post a comment
Trending Stocks
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
PROG Holdings Stock Forum
• $American Express (AXP.US)$ : Baird Upgrades to Outperform from Neutral - PT $175
• $The AZEK (AZEK.US)$ : BofA Securities Upgrades to Buy from Neutral
• $Capital One Financial (COF.US)$ : Baird Upgrades to Outperform from Neutral - PT $145
• $Fifth Third Bancorp (FITB.US)$ : Baird Upgrades to Outperform from Neutral - PT $44
• $M&T Bank (MTB.US)$ : Baird Upgrades to Outperform from Neutral - PT $200 (from $175)
• $NextEra Energy Partners LP (NEP.US)$ : RBC Cap...
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...
No comment yet